PL2611831T3 - Leczenie zawału mięśnia sercowego z zastosowaniem antagonistów TGF-beta - Google Patents

Leczenie zawału mięśnia sercowego z zastosowaniem antagonistów TGF-beta

Info

Publication number
PL2611831T3
PL2611831T3 PL11758276T PL11758276T PL2611831T3 PL 2611831 T3 PL2611831 T3 PL 2611831T3 PL 11758276 T PL11758276 T PL 11758276T PL 11758276 T PL11758276 T PL 11758276T PL 2611831 T3 PL2611831 T3 PL 2611831T3
Authority
PL
Poland
Prior art keywords
tgf
treatment
myocardial infarction
beta antagonists
antagonists
Prior art date
Application number
PL11758276T
Other languages
English (en)
Inventor
Geoffrey Y. Akita
Scott Lonning
Richard C. Gregory Jr.
Amelia B. Kudej
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PL2611831T3 publication Critical patent/PL2611831T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
PL11758276T 2010-09-01 2011-09-01 Leczenie zawału mięśnia sercowego z zastosowaniem antagonistów TGF-beta PL2611831T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37931510P 2010-09-01 2010-09-01
EP11758276.7A EP2611831B1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf-beta antagonists
PCT/US2011/001536 WO2012030394A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Publications (1)

Publication Number Publication Date
PL2611831T3 true PL2611831T3 (pl) 2019-05-31

Family

ID=44654454

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11758276T PL2611831T3 (pl) 2010-09-01 2011-09-01 Leczenie zawału mięśnia sercowego z zastosowaniem antagonistów TGF-beta

Country Status (18)

Country Link
US (2) US20130330352A1 (pl)
EP (1) EP2611831B1 (pl)
JP (2) JP6377348B2 (pl)
KR (1) KR101939965B1 (pl)
CN (1) CN103201292B (pl)
BR (1) BR112013004850B1 (pl)
CA (1) CA2809568C (pl)
CL (1) CL2013000586A1 (pl)
ES (1) ES2715177T3 (pl)
IL (1) IL225018A (pl)
MX (1) MX354535B (pl)
MY (1) MY165160A (pl)
NZ (2) NZ608813A (pl)
PL (1) PL2611831T3 (pl)
RU (1) RU2637088C2 (pl)
SG (2) SG187953A1 (pl)
TR (1) TR201903101T4 (pl)
WO (1) WO2012030394A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010216095B2 (en) * 2009-02-18 2015-10-08 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
EP2971048B1 (en) 2013-03-11 2018-10-31 Genzyme Corporation Engineered anti-tgf-beta antibodies and antigen-binding fragments
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
CA2971186A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US9884900B2 (en) 2015-08-04 2018-02-06 Acceleron Pharma Inc. Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
DK3368571T3 (da) * 2015-10-30 2023-01-23 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
TW201726744A (zh) 2016-01-11 2017-08-01 奧托德里克有限公司 用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
WO2018027329A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
FI3628049T3 (fi) 2017-05-04 2023-07-26 Acceleron Pharma Inc Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä
AU2022355276A1 (en) 2021-09-30 2024-05-16 Peptidream Inc. Peptide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
MXPA06011199A (es) * 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
EP1848424B1 (en) 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
TR201901929T4 (tr) * 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido

Also Published As

Publication number Publication date
TR201903101T4 (tr) 2019-03-21
US20170233465A1 (en) 2017-08-17
US10633437B2 (en) 2020-04-28
MX354535B (es) 2018-03-09
NZ624382A (en) 2015-05-29
IL225018A (en) 2017-11-30
JP2013542179A (ja) 2013-11-21
EP2611831B1 (en) 2018-12-12
ES2715177T3 (es) 2019-06-03
RU2013114365A (ru) 2014-10-10
CL2013000586A1 (es) 2013-08-30
BR112013004850A2 (pt) 2016-05-31
MX2013002390A (es) 2013-08-27
CA2809568C (en) 2019-06-11
WO2012030394A1 (en) 2012-03-08
JP6377348B2 (ja) 2018-08-22
MY165160A (en) 2018-02-28
KR101939965B1 (ko) 2019-01-18
SG187953A1 (en) 2013-03-28
RU2637088C2 (ru) 2017-11-29
CN103201292A (zh) 2013-07-10
EP2611831A1 (en) 2013-07-10
AU2011296574B2 (en) 2015-12-03
JP2017193543A (ja) 2017-10-26
SG10201506909PA (en) 2015-10-29
CN103201292B (zh) 2016-09-14
BR112013004850B1 (pt) 2020-04-07
NZ608813A (en) 2014-11-28
AU2011296574A1 (en) 2013-03-21
US20130330352A1 (en) 2013-12-12
CA2809568A1 (en) 2012-03-08
KR20130111550A (ko) 2013-10-10

Similar Documents

Publication Publication Date Title
SG10201506909PA (en) Treatment of myocardial infarction using tgf - beta antagonists
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
EP2627178A4 (en) QUINAZOLINONE-LIKE COMPOUNDS AS CRTH2 ANTAGONISTS
PL3222272T3 (pl) Kompozycje farmaceutyczne karbetocyny
AP3030A (en) Propynylaminoindan transdermal compositions
HK1175171A1 (en) Compounds as bradykinin b1 antagonists b1
EP2526772A4 (en) COMPOSITION FOR MULTIFUNCTION SURFACE TREATMENT
PL2534302T3 (pl) Kompozycja do obróbki powierzchni
IL222072A (en) Composition for the treatment of primary thrombocythemia
PL2460509T3 (pl) Kompozycja do leczenia brodawek
EP2634213A4 (en) OLEFIN COMPOSITION
TWM401347U (en) Improved structure of brush
HK1160777A1 (en) Novel use of neohesperidoside
ZA201209076B (en) Laundry treatment composition
TWM389753U (en) Improved structure of handle
HK1133781A2 (en) One kind of toothbrushes
HU1000688D0 (en) Use of trifluoro-phal
HK1200443A1 (en) Compounds as bradykinin b1 antagonists b1
TWM390770U (en) Preheater of endoscope
TWM385541U (en) Improved structure of container
TWM386872U (en) Improvement of mop structure
TWM400763U (en) Improved structure of cold-accumulating cravats
TWM388315U (en) Improved structure of hemoclip
TWM390721U (en) Sharing cup
TWM385962U (en) Structure of handle for cane-configured umbrella